IN 2021, DAMON RUNYON SCIENTISTS CONTINUED TO BLAZE NEW TRAILS IN THE LABORATORY AND THE CLINIC AS WE ENTER OUR 75TH YEAR OF FUNDING BRAVE AND BOLD CANCER RESEARCH.

THIS YEAR ALONE, DAMON RUNYON SCIENTISTS:

- Developed a prognostic tool that can detect lingering tumor DNA in the bloodstream after treatment.
- Discovered the presence of sugar-coated RNA on the cell surface, illuminating a potential immune signaling mechanism that can be used to improve immunotherapies.
- Demonstrated that depriving kidney cancer cells of cholesterol results in tumor shrinkage, suggesting a new method of treating kidney cancer.
- Conducted clinical trials for a new leukemia drug that can treat patients as young as one month old and may one day be used as a preventative therapy.
- Received FDA approval for the first drug to inhibit KRAS, an oncprotein long considered an “undruggable” cancer target, for the treatment of lung cancer.

AWARDS AND HONORS

Former Damon Runyon Fellow and Scholar Ardem Patapoutian, PhD, and former Fellowship Award Committee member David Julius, PhD, received the 2021 Nobel Prize in Physiology or Medicine.

Damon Runyon alumni newly elected to the National Academy of Sciences (the science “Hall of Fame”) are Nenad Ban, PhD, Geeta J. Narlikar, PhD, and Eileen P. White, PhD.

Alumni elected to the prestigious National Academy of Medicine are William C. Hahn, MD, PhD, Peter Tontonoz, MD, PhD, Cynthia Wolberger, PhD, and Feng Zhang, PhD.

Damon Runyon Clinical Investigators elected to The American Society for Clinical Investigation, one of the nation’s oldest and most prestigious medical honor societies, are Himisha Beltran, MD, Ami S. Bhatt, MD, PhD, Jaehyuk Choi, MD, PhD, Alejandro Gutierrez, MD, and Piro Lito, MD, PhD.

Damon Runyon Clinical Investigator Piro Lito, MD, PhD, received the 2021 Trailblazer Prize for Clinician-Scientists from the Foundation for the National Institutes of Health.

Damon Runyon-HHMI Fellow Tyler Starr, PhD, was named a 2021 STAT Wunderkind, celebrating young researchers on the cusp of launching independent careers.
OUR MISSION
At the Damon Runyon Cancer Research Foundation, we fund high-risk, high-reward cancer research. We identify and enable young scientists who are brilliant, brave, and bold enough to go where others haven’t.

RESEARCH PROGRAMS
• We are currently funding **196 researchers** at **50 institutions** across the nation.
• In fiscal year 2021, we awarded nearly **$18.1 million** in new grants to **60 exceptional scientists**.

FINANCIAL INFORMATION

TOTAL REVENUE:
$21 MILLION

- Investment Return 21.1%
- Contributions 60.6%
- Misc. Income 4.6%
- Bequests & Trusts 13.7%
- Damon Runyon Broadway Tickets 0%

TOTAL EXPENSES:
$21 MILLION

- Award Programs 87.2%
- Fundraising 8.6%
- General Administration 4.2%

100% OF YOUR DONATION FUNDS BRILLIANT SCIENTISTS.
We pay our low overhead with revenue from Damon Runyon Broadway Tickets and our endowment.